3 Vaccine Stocks With Big Opportunities Outside of COVID-19
Vaccine-focused biotech stocks have been amazing performers over the last couple of years -- particularly if you owned the right ones. Novavax (NASDAQ: NVAX) jumped from a micro-cap to a $12 billion valuation. And of course, mRNA vaccine specialists have been on fire. Moderna (NASDAQ: MRNA) is now worth $94 billion, and BioNTech (NASDAQ: BNTX) has grown to a $58 billion valuation. Even tiny Vir Bio (NASDAQ: VIR) has crushed the market: It's up by 144% over the past two years.
Of course, it was COVID-19 that caused this segment of the healthcare sector to skyrocket. But there are a lot of other ugly diseases out there, and effective vaccines could knock some of them out, too. We asked three of our contributors which companies in this niche they're bullish on now: Their picks: Novavax, Moderna, and Vir Bio.
image source: Getty Images
Source Fool.com
